Current/ Expected Orderbook/ Pending Orders?

The company has already had multiple rounds of conversations about demand from RFQ customers for H1 2025. The numbers for H1 2025 demand appear healthy based on these discussions. Positive feedback and substantial interest have been shown by global distributors and spot customers, especially for hydrogenation products. The onboarding of RFQ customers for the Vadodara Hydrogenation Plant is expected in H2 2025. Overall, the sales forecast for the Speciality Aroma Ingredients division remains strong. New product launches and existing customer growth contribute to a healthy order pipeline. The co

Any current/future new fundraising through debt or equity?

There is no specific mention of any current or planned fundraising through debt or equity in the transcript. The company reported a net debt-to-equity ratio of 0.35 as of 30 September 2024, indicating a moderate debt level. Discussions in the call focused on operational performance, expansions, and new product launches without reference to raising funds. The company appears to be financing ongoing expansions like the Mahad Greenfield project and Vadodara hydrogenation plant from existing resources. If there are any developments related to fundraising, the management stated they would inform th

Any current/future capex/capital investment/strategic investment?

Commercial production started at the Greenfield site in Mahad, Maharashtra, in November 2024, dedicated to producing a specialty aroma ingredient called Evermoss. Investment at Mahad includes substantial plot development and infrastructure, with around 50-55% of costs toward the plot and utility block; approximately ₹70-75 crores directly invested in the product. Hydrogenation plant at Vadodara commissioned in July 2024, currently operating at about 30% capacity; onboarding of RFQ customers expected in H2 2025. Future expansions beyond the current announced phase at Mahad are not decided

Future growth expectations in sales/revenue/volumes?

The company expects steady growth across all three verticals—fragrance and flavor, speciality aroma ingredients, and camphor—with the fragrance and flavor division growing through new customer acquisitions and product launches. Hydrogenation plant at Vadodara is operating at about 30% capacity; onboarding of RFQ customers is expected in H2 FY25, which will support top-line growth. Greenfield facility in Mahad commenced production in November 2024, focusing on specialty aroma ingredient Evermoss, expected to generate significant revenues—projected 160 to 200 crores from this molecule alone. Com

Future growth expectations in earnings/operating earnings/profits/EPS?

The company expects steady demand growth across fragrance, flavor, and specialty aroma ingredients divisions, supported by new customer acquisitions and product launches. EBITDA margin guidance is cautiously optimistic, maintaining a 10-12% range due to new plants and products stabilizing. Expansion projects like the Vadodara hydrogenation plant and Mahad Greenfield site are expected to add ₹250-300 crores to top-line over the next 2-3 years. Hydrogenation and specialty aroma ingredients are expected to offer healthy margins, contributing positively to overall profitability. Camphor segment re

IN US

Sale is live|00:00:00left today

Oriental Aromatics LtdQ3 FY24Chemicals & Petrochemicals

Oriental Aromatics Ltd Q3 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹324P/E: 1440.7Market Cap: ₹1.1K CrSector: Chemicals & Petrochemicals

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

Yes

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 3

→The company expects steady growth across all three verticals—fragrance and flavor, speciality aroma ingredients, and camphor—with the fragrance and flavor division growing through new customer acquisitions and product launches.
→Hydrogenation plant at Vadodara is operating at about 30% capacity; onboarding of RFQ customers is expected in H2 FY25, which will support top-line growth.
→Greenfield facility in Mahad commenced production in November 2024, focusing on specialty aroma ingredient Evermoss, expected to generate significant revenues—projected 160 to 200 crores from this molecule alone.
→Combined expansions (Vadodara hydrogenation, Mahad Greenfield, process reengineering) may contribute an additional ₹250-300 crores in top line over the next 2-3 years.
→Overall, growth of 5-10% is anticipated in existing businesses in H2 FY25, though camphor remains seasonal and demand will be monitored.
→The company aims for a cautious but positive outlook in demand and revenue growth through product portfolio expansion and market penetration.

Margin guidance

Category 3

→The company expects steady demand growth across fragrance, flavor, and specialty aroma ingredients divisions, supported by new customer acquisitions and product launches.
→EBITDA margin guidance is cautiously optimistic, maintaining a 10-12% range due to new plants and products stabilizing.
→Expansion projects like the Vadodara hydrogenation plant and Mahad Greenfield site are expected to add ₹250-300 crores to top-line over the next 2-3 years.
→Hydrogenation and specialty aroma ingredients are expected to offer healthy margins, contributing positively to overall profitability.
→Camphor segment remains seasonal and price-volatile, which may impact margins intermittently.
→Demand outlook for H1 2025 is robust, supporting positive earnings momentum.
→The company aims to sustain double-digit EBITDA margins and improve profitability from current 12.08% quarterly margin and strong H1 FY25 performance.
→Net profit for H1 FY25 improved significantly, signaling confidence in future earnings growth.

3 more insights locked — sign up free to unlock

Fundraise plans

→There is no specific mention of any current or planned fundraising through debt or equity in the transcript.
→The company reported a net debt-to-equity ratio of 0.35 as of 30 September 2024, indicating a moderate debt level.
→Discussions in the call focused on operational performance, expansions, and new product launches without reference to raising funds.
→The company appears to be financing ongoing expansions like the Mahad Greenfield project and Vadodara hydrogenation plant from existing resources.
→If there are any developments related to fundraising, the management stated they would inform the investor community accordingly.

Order book

Yes

→The company has already had multiple rounds of conversations about demand from RFQ customers for H1 2025.
→The numbers for H1 2025 demand appear healthy based on these discussions.
→Positive feedback and substantial interest have been shown by global distributors and spot customers, especially for hydrogenation products.
→The onboarding of RFQ customers for the Vadodara Hydrogenation Plant is expected in H2 2025.
→Overall, the sales forecast for the Speciality Aroma Ingredients division remains strong.
→New product launches and existing customer growth contribute to a healthy order pipeline.
→The company remains cautiously optimistic but confident about capturing a substantial share of the global market for new products, such as Evermoss from the Mahad Greenfield site.

Capex plans

Yes

→Commercial production started at the Greenfield site in Mahad, Maharashtra, in November 2024, dedicated to producing a specialty aroma ingredient called Evermoss.
→Investment at Mahad includes substantial plot development and infrastructure, with around 50-55% of costs toward the plot and utility block; approximately ₹70-75 crores directly invested in the product.
→Hydrogenation plant at Vadodara commissioned in July 2024, currently operating at about 30% capacity; onboarding of RFQ customers expected in H2 2025.
→Future expansions beyond the current announced phase at Mahad are not decided yet; the company will update investors as applicable.
→Total revenue from expansions (Vadodara hydrogenation, Mahad, process reengineering) expected to add ₹250-300 crores in the next 2-3 years.
→Depreciation from the Mahad plant estimated at ₹5-6 crores per year from Q4 FY25.

How does Oriental Aromatics Ltd rank vs peers in Chemicals & Petrochemicals?

Pro feature

1Oriental Aromatics Ltd

Rev 3Mar 3

See full Chemicals & Petrochemicals sector rankings

Want more stocks like Oriental Aromatics Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio